Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...
Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these ...
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a new study has ...
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.
GLP-1 medications such as Ozempic and Wegovy have had a transformative effect for those struggling with weight loss. Many ...
The number of prescriptions for anti-obesity GLP-1 drugs like Wegovy and Ozempic is rising in North Carolina, just as it is nationwide — a trend that could have substantial effects on a range of ...
New poll shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs if they are ...
(CNN) — Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections ...